GSK’s Blenrep Wins BCMA Race, Carries Ocular Toxicity Warning
Executive Summary
US FDA-approved belantamab mafodotin is indicated for heavily pre-treated multiple myeloma and has a list price of $23,900 per month. Its REMS could limit initial uptake, but response rates have been encouraging.
You may also be interested in...
Approval Of BMS/Bluebird’s Ide-Cel May Come Just In Time
In last year’s acquisition, Bristol Myers Squibb agreed to pay Celgene investors another $9 per share based on three approvals, including idecabtagene vicleucel (bb2121) by 30 March 2021.
Keeping Track: Four Novel Agents Clear US FDA, Including Evrysdi, Blenrep
The latest US FDA approvals and actions from the Pink Sheet’s US FDA Performance Tracker.
GlaxoSmithKline Spotlights Immune System And Oncology R&D
New oncology and immunology products are moving rapidly through GSK’s refocused research pipeline, including new agents for multiple myeloma, endometrial and head and neck cancer, adding to efforts against COVID-19, respiratory syncytial virus infection and HIV/AIDS.
Need a specific report? 1000+ reports available Buy Reports